<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167267</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012102</org_study_id>
    <nct_id>NCT04167267</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers (II)</brief_title>
  <official_title>A Randomized, Open-label, Single Dose Study to Evaluate the Safety and Pharmacokinetics of DWP14012 Tablet A and DWP14012 Tablet B in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single dose study to evaluate the safety and
      pharmacokinetics of DWP14012 tablet A and DWP14012 tablet B in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt: Area under the drug concentration-time curve from time 0 to tau (dosing interval)</measure>
    <time_frame>0 hour (pre-dose), 0.5 hour, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour, 24 hour, 48 hour</time_frame>
    <description>each period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Peak concentration of DWP14012</measure>
    <time_frame>0 hour (pre-dose), 0.5 hour, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour, 24 hour, 48 hour</time_frame>
    <description>each period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf: Area under the drug concentration-time curve from time 0 to infinity</measure>
    <time_frame>0 hour (pre-dose), 0.5 hour, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour, 24 hour, 48 hour</time_frame>
    <description>each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time of maximum concentration</measure>
    <time_frame>0 hour (pre-dose), 0.5 hour, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour, 24 hour, 48 hour</time_frame>
    <description>each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: Terminal elimination half-life</measure>
    <time_frame>0 hour (pre-dose), 0.5 hour, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour, 24 hour, 48 hour</time_frame>
    <description>each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apperent Clearance</measure>
    <time_frame>0 hour (pre-dose), 0.5 hour, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour, 24 hour, 48 hour</time_frame>
    <description>each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F: Apparent volume of distribution</measure>
    <time_frame>0 hour (pre-dose), 0.5 hour, 1 hour, 1.5 hour, 2 hour, 2.5 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour, 24 hour, 48 hour</time_frame>
    <description>each period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (Tablet B - Tablet A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : DWP14012 tablet B Period 2: DWP14012 tablet A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (Tablet A - Tablet B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : DWP14012 tablet A Period 2: DWP14012 tablet B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 tablet A</intervention_name>
    <description>Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A</description>
    <arm_group_label>Sequence 1 (Tablet B - Tablet A)</arm_group_label>
    <arm_group_label>Sequence 2 (Tablet A - Tablet B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 tablet B</intervention_name>
    <description>Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B</description>
    <arm_group_label>Sequence 1 (Tablet B - Tablet A)</arm_group_label>
    <arm_group_label>Sequence 2 (Tablet A - Tablet B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult aged between 19 and 45 at screening

          -  Those whose weight is 55 kg and more and BMI is between 17.5 and 30.5 kg/m2

          -  Subjects who are adequate to be subjects in this study upon judgment of the
             investigator after physical examination, clinical laboratory test, examination by
             interview, etc

        Exclusion Criteria:

          -  Subjects who have clinical significant liver, kidney, nervous system, respiratory,
             endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or
             past history

          -  Subjects who have gastrointestinal diseases or past history of gastrointestinal
             diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux,
             Crohn's disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic
             evaluation of study drug, and those who have past history of gastrointestinal surgery
             (however, except simple ppendectomy and herniotomy)

          -  Subjects who showed positive result for Helicobacter pylori test

          -  Subjects with serum AST (SGOT) or ALT (SGPT) level &gt;1.5 times the upper limit of the
             normal range at the time of the screening examination

          -  Subjects with a history of drug abuse or a positive urine screening for drug abuse

          -  Subjects who have participated and taken investigational drug in any other clinical
             trial (including bioequivalence study) within six months prior to study drug
             administration

          -  Subjects who have donated a unit of whole blood within two months or blood components
             within one month prior to study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim</last_name>
      <phone>82-63-259-3480</phone>
      <email>irb@cuh.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

